Pharmaceutical Group Zendal Expands Vaccine Manufacturing Capacity
- The firm will inaugurate a center this summer in Portugal
Zendal’s Expansion Plans
The pharmaceutical group Zendal is set to expand its current vaccine manufacturing capacity this year. To achieve this, the group will establish a dedicated center in the north of Portugal solely for the production of serums for human health. The Portuguese Medicines Agency is expected to grant the necessary licenses for operation during the summer.
Manufacturing for Third Parties
Initially, the new factory will focus on manufacturing vaccines for third parties. One of the significant contracts secured by Zendal is with Novavax to produce the antigen for the American vaccine against the coronavirus. In the future, the company also plans to manufacture a serum for pulmonary tuberculosis, which is currently in the final phase of a clinical trial.
Shareholders Meeting and Financial Performance
During the recent shareholders meeting, Zendal revealed its current turnover. The group closed last year with a turnover of 120.1 million euros. In addition, 2022 marked a year of management reorganization, with the establishment of the general management position and Global Operations Management.
Comments
0WhatsApp
Twitter
Linkedin
read comments
COVID-19. This partnership is part of the European Union’s strategy to ensure the production of vaccines within its member states. The new center in Portugal will allow Zendal to fulfill this contract and contribute to vaccine production for the global market.
Zendal’s Commitment to Vaccine Manufacturing
Zendal is a Spanish pharmaceutical group that specializes in biotechnology, with a particular focus on vaccine production. The expansion of its manufacturing capacity in Portugal is a testament to the group’s commitment to meeting the growing demand for vaccines, particularly in the wake of the COVID-19 pandemic. With its state-of-the-art facilities and expertise in biotechnology, Zendal aims to contribute to the global effort in vaccinating populations against various diseases.
The pharmaceutical group Zendal is set to expand its vaccine manufacturing capacity by establishing a dedicated center in Portugal. This center will focus on producing serums for human health and initially manufacture vaccines for third parties. One of the significant contracts secured by Zendal is with Novavax to produce the antigen for the American vaccine against COVID-19. The expansion in Portugal demonstrates Zendal’s commitment to meeting the global demand for vaccines and its expertise in biotechnology. With the new center, Zendal aims to contribute to the vaccination efforts against various diseases.
What are the benefits of Zendal’s partnership with Novavax for the production of the antigen for the American COVID-19 vaccine
Zendal’s partnership with Novavax for the production of the antigen for the American COVID-19 vaccine brings several benefits.
1. Increased production capacity: Novavax’s NVX-CoV2373 vaccine has shown promising results in clinical trials. By partnering with Novavax, Zendal can leverage their expertise in vaccine development and manufacturing to ramp up the production of the antigen. This will help in meeting the high demand for the COVID-19 vaccine and ensure sufficient supply for the American population.
2. Quick response to emerging variants: The partnership allows for efficient adaptation to emerging variants of the COVID-19 virus. The Novavax vaccine has demonstrated efficacy against multiple variants, and Zendal’s production capabilities can be utilized to manufacture updated versions of the antigen if required. This flexibility ensures that the vaccine remains effective against new strains and helps in controlling the spread of the virus.
3. Global distribution: The collaboration between Zendal and Novavax enables a global distribution network for the COVID-19 vaccine. Zendal has a strong international presence and extensive experience in biopharmaceutical manufacturing, which will facilitate the distribution of the vaccine to various countries worldwide. This partnership plays a key role in ensuring equitable access to the vaccine and helps in combating the global pandemic.
4. Technology transfer and knowledge sharing: Through the partnership, Zendal can gain valuable knowledge and expertise in vaccine production techniques from Novavax. This technology transfer can enhance Zendal’s capabilities in vaccine development and manufacturing, enabling them to contribute to future vaccine production efforts for other diseases. The collaboration fosters mutual learning and growth in the field of biopharmaceutical manufacturing.
Overall, the partnership between Zendal and Novavax for the production of the COVID-19 vaccine antigen brings increased production capacity, adaptability to emerging variants, global distribution capabilities, and opportunities for knowledge sharing and growth in the biopharmaceutical sector.
1 comment
Zendal Expand seems to be an exciting development with great potential. Looking forward to seeing how it can revolutionize businesses and industries.